Prague medical report
-
Prague medical report · Jan 2006
Case ReportsEnd tidal CO2 monitoring in condition of constant ventilation: a useful guide during advanced cardiac life support.
Success of advanced cardiac life support (ACLS) depends on several factors: character and severity of the primary insult, time interval between cardiac arrest and effective basic life support (BLS) and the ensuing ACLS, patient's general condition before the insult, environmental circumstances and efficacy of BLS and ACLS. From these factors, only the efficacy of ACLS is under control of emergency personnel. The end tidal partial pressure of CO2 (P(ET)CO2) has been shown to be an indicator of the efficiency of ACLS and a general prognostic marker. ⋯ The aetiology included lung oedema, tension pneumothorax and high voltage electric injury. P(ET)CO2 served for adjustments of ACLS. In these three cases the predictive value of P(ET)CO2 monitoring corresponded to previously reported recommendations.
-
The restless legs syndrome (RLS) is a sensorimotor disorder characterised by an intense urge to move the legs and sometimes also other parts of the body, and accompanied by a marked sense of discomfort or pain in the affected body parts. This urge has a circadian pattern - it is most pronounced in the evening or during the night. RLS symptoms are relieved by movement. ⋯ RLS is curable, though the choice of therapy and proper dosage titration may take a long time, and though the therapy may sometimes have to be changed owing to augmentation. The most important pharmacologic treatment used in RLS includes L-DOPA, dopamine agonists, opiates, anticonvulsants and benzodiazepines. Therapy improves significantly the condition in long-term at least in 80% of RLS patients.
-
Prague medical report · Jan 2004
Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia.
Thrombocytopenic patients refractory to platelet concentrates (PC) could be treated during bleeding episodes with the recombinant activated FVII (rFVIIa). However, monitoring of administration of the rFVIIa or a response to platelet substitution therapy in thrombocytopenia patients is not well documented so far. Using of whole blood ROTEG analysis we monitored the changes in haemostatic parameters following in vivo platelet concentrate administration compared to ex vivo rFVIIa administration in patients with a severe to mild thrombocytopenia secondary to haemato-oncological disease. ⋯ When we compared the effect of platelet vs. rFVIIa treated whole blood by NATEG analysis we did not found any significant difference. Analysis with INTEG system was less sensitive and changes in CT and CFT were not significant. The monitoring with thrombelastography could enable efficient application of platelet concentrate and furthermore the using of rFVIIa as an alternative treatment of patients refractory to platelet infusion or with allergic reactions.